Jump Financial, LLC Macrogenics Inc Transaction History

Jump Financial, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Oct 21, 2024	SELL	$4.48 - $10.11 $363,507 - $820,325	-81,140 Reduced 85.23%	14,060 $135,000
Q4 2023 Feb 07, 2024	BUY	$4.48 - $10.11 $62,988 - $142,146	14,060 New	14,060 $135,000
Q1 2023 Oct 21, 2024	BUY	$4.82 - $7.24 $458,864 - $689,248	95,200 New	95,200 $682,000
Q1 2023 May 03, 2023	BUY	$4.82 - $7.24 $218,403 - $328,058	45,312 Added 90.83%	95,200 $682,000
Q4 2022 Feb 13, 2023	BUY	$3.34 - $6.98 $14,321 - $29,930	4,288 Added 9.4%	49,888 $334,000
Q3 2022 Nov 07, 2022	SELL	$3.01 - $5.22 $39,732 - $68,904	-13,200 Reduced 22.45%	45,600 $158,000
Q2 2022 Aug 09, 2022	BUY	$2.25 - $9.99 $17,550 - $77,922	7,800 Added 15.29%	58,800 $173,000
Q1 2022 May 12, 2022	BUY	$8.12 - $16.9 $128,823 - $268,118	15,865 Added 45.15%	51,000 $449,000
Q4 2021 Feb 10, 2022	BUY	$15.91 - $21.88 $558,997 - $768,753	35,135 New	35,135 $563,000
Q2 2021 Aug 13, 2021	SELL	$20.49 - $35.63 $167,423 - $291,132	-8,171 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $155,167 - $271,277	8,171 New	8,171 $260,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $202M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.